Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin’s Lymphoma (NHL)

Primary Inclusion Criteria:

Relapsed or refractory histologically confirmed Non-Hodgkin's Lymphoma
Previously treated with at least 1 therapeutic regimen and relapsed or progressed or failed to achieve a response after the last regimen
18 years of age or older

Primary Exclusion Criteria:

Received a non-FDA approved investigational agent within the last 4 weeks
Received cancer therapies (chemotherapy, biological therapy [including hormonotherapy], radiation therapy or immunosuppressants within the last 3 weeks, 8 weeks for monoclonal antibodies, radioimmunotherapy or nitrosourea
Eligible for a hematopoietic stem cell transplant (HSCT) or have had an autologous HSCT within the last 16 weeks
Prior history of an allogeneic HSCT
HIV, AIDS-related lymphoma, central nervous system (CNS) lymphoma, Hepatitis-B or Hepatitis-C
Infection requiring antibiotics within the last 4 weeks
Major surgery within the last 4 weeks
Pregnant or breast-feeding women
History of other cancers within the past 5 years